Published in Mol Ther Nucleic Acids on July 09, 2013
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | NCT03706547
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunol Res (2016) 1.44
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
CAR T cells for solid tumors: armed and ready to go? Cancer J (2014) 1.29
Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol (2015) 1.18
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A (2016) 1.09
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther (2014) 1.08
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica (2015) 1.02
Engineering CAR-T cells: Design concepts. Trends Immunol (2015) 0.93
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol (2015) 0.92
Adoptive cell therapies for glioblastoma. Front Oncol (2013) 0.90
Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep (2014) 0.89
Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel) (2015) 0.89
The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer (2014) 0.85
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
The Evolution of T-cell Therapies for Solid Malignancies. Clin Cancer Res (2015) 0.84
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest (2016) 0.84
Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013. Hum Gene Ther (2014) 0.82
Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol (2015) 0.82
CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics (2016) 0.81
CAR T Cell Therapy: A Game Changer in Cancer Treatment. J Immunol Res (2016) 0.81
Genetically modified T cells to target glioblastoma. Front Oncol (2013) 0.80
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology (2015) 0.80
Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther (2016) 0.79
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J (2016) 0.78
Synthetic biology approaches to engineer T cells. Curr Opin Immunol (2015) 0.78
New development in CAR-T cell therapy. J Hematol Oncol (2017) 0.78
Cellular immunotherapy for pediatric solid tumors. Cytotherapy (2014) 0.77
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. J Immunol Res (2016) 0.76
Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma. Mol Ther (2015) 0.76
Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. J Immunother Cancer (2015) 0.76
Antigen Loss Variants: Catching Hold of Escaping Foes. Front Immunol (2017) 0.75
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep (2017) 0.75
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med (2017) 0.75
Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them. Cancer Gene Ther (2016) 0.75
A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer (2017) 0.75
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside. Oncoimmunology (2016) 0.75
An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep (2017) 0.75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol (2017) 0.75
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia. Front Pediatr (2015) 0.75
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol (2017) 0.75
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
3D-Jury: a simple approach to improve protein structure predictions. Bioinformatics (2003) 7.99
PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res (2005) 7.66
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 5.66
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant (2010) 3.79
ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res (2010) 2.96
FireDock: fast interaction refinement in molecular docking. Proteins (2007) 2.90
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol (2012) 1.71
HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res (2010) 1.65
Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res (2007) 1.58
Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer (2001) 1.46
Optimization of the Tet-On system for regulated gene expression through viral evolution. Gene Ther (2006) 1.42
Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev (2005) 1.41
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther (2009) 1.40
Analyzing protein interaction networks using structural information. Annu Rev Biochem (2008) 1.32
Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res (2010) 1.31
Exploring folding free energy landscapes using computational protein design. Curr Opin Struct Biol (2004) 1.27
Theoretical and computational protein design. Annu Rev Phys Chem (2011) 1.26
Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther (2000) 1.24
Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A (2010) 1.24
Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer (2004) 1.19
The GeneOptimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Syst Synth Biol (2010) 1.18
Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci U S A (2010) 1.16
Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology (N Y) (1992) 1.15
Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost (2009) 1.12
Dynamics of protein folding: probing the kinetic network of folding-unfolding transitions with experiment and theory. Biochim Biophys Acta (2010) 1.09
Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen. J Mol Biol (2009) 1.01
Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol (1991) 0.98
Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res (2005) 0.96
Flexible structures and ligand interactions of tandem repeats consisting of proline, glycine, asparagine, serine, and/or threonine rich oligopeptides in proteins. Curr Protein Pept Sci (2008) 0.95
Computational design of membrane proteins. Structure (2012) 0.95
Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J Immunol (1997) 0.91
High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development. J Biol Chem (2009) 0.90
Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Methods Enzymol (2012) 0.88
Chimeric antigen receptor-modified T cells in CLL. N Engl J Med (2011) 0.86
T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors. Cancer Gene Ther (2000) 0.84
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Outcome of the first electron microscopy validation task force meeting. Structure (2012) 4.35
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood (2004) 4.01
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
Backbone structure of the infectious epsilon15 virus capsid revealed by electron cryomicroscopy. Nature (2008) 3.54
De novo backbone trace of GroEL from single particle electron cryomicroscopy. Structure (2008) 3.41
EMDataBank.org: unified data resource for CryoEM. Nucleic Acids Res (2010) 3.32
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Refinement of protein structures into low-resolution density maps using rosetta. J Mol Biol (2009) 2.94
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
CARs on track in the clinic. Mol Ther (2011) 2.86
Mechanism of folding chamber closure in a group II chaperonin. Nature (2010) 2.85
Post-transplant lymphoproliferative disorders. Annu Rev Med (2005) 2.82
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
Coat protein fold and maturation transition of bacteriophage P22 seen at subnanometer resolutions. Nat Struct Biol (2003) 2.76
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant (2007) 2.33
4.0-A resolution cryo-EM structure of the mammalian chaperonin TRiC/CCT reveals its unique subunit arrangement. Proc Natl Acad Sci U S A (2010) 2.17
Electron cryomicroscopy of biological machines at subnanometer resolution. Structure (2005) 2.15
Adoptive T cell therapy of cancer. Curr Opin Immunol (2010) 2.13
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Structural changes in a marine podovirus associated with release of its genome into Prochlorococcus. Nat Struct Mol Biol (2010) 2.12
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood (2007) 2.11
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood (2010) 2.06
Refinement of protein structures by iterative comparative modeling and CryoEM density fitting. J Mol Biol (2006) 2.06
Structural basis for scaffolding-mediated assembly and maturation of a dsDNA virus. Proc Natl Acad Sci U S A (2011) 2.03
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood (2002) 1.98
Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant (2009) 1.97
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood (2013) 1.95
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 1.93
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood (2002) 1.89
Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer (2007) 1.85
Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. Exp Hematol (2012) 1.85
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother (2010) 1.81
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
4.4 Å cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus. EMBO J (2011) 1.77
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med (2004) 1.72
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther (2012) 1.72
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood (2011) 1.72
A 9 angstroms single particle reconstruction from CCD captured images on a 200 kV electron cryomicroscope. J Struct Biol (2004) 1.70
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol (2007) 1.70
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res (2011) 1.70
Subnanometer-resolution electron cryomicroscopy-based domain models for the cytoplasmic region of skeletal muscle RyR channel. Proc Natl Acad Sci U S A (2008) 1.68
Structural characterization of components of protein assemblies by comparative modeling and electron cryo-microscopy. J Struct Biol (2005) 1.67
HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res (2010) 1.65
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther (2010) 1.64
Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma (2010) 1.64
Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res (2007) 1.58
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood (2004) 1.57
T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood (2012) 1.55
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood (2003) 1.55
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood (2008) 1.52
Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes. J Immunol (2010) 1.50
Applications of a bilateral denoising filter in biological electron microscopy. J Struct Biol (2003) 1.50
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother (2010) 1.50
The C terminus of the Alb3 membrane insertase recruits cpSRP43 to the thylakoid membrane. J Biol Chem (2009) 1.49
Rotavirus architecture at subnanometer resolution. J Virol (2008) 1.48
Safer CARS. Mol Ther (2010) 1.46
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma (2006) 1.46
Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol (2007) 1.45